Morgan Thompson
@morgankthomp.bsky.social
Philosopher of Science. Interested in measurement, technology, data ethics, and social change. Enjoys games, sci fi, cats. She/her
hope you had a big lunch!
November 23, 2025 at 1:28 AM
hope you had a big lunch!
The anatomy courses in question:
Today in AI Is Not A Good Source For Learning About The World's Most Misunderstood Body Part, meet this ChatGPT gem.
Funnily enough, we're actually going to talk about how most of this is kinda sorta right (for small values of right), as a cautionary tale about generative AI.
Funnily enough, we're actually going to talk about how most of this is kinda sorta right (for small values of right), as a cautionary tale about generative AI.
November 20, 2025 at 12:17 AM
The anatomy courses in question:
Reposted by Morgan Thompson
This is a frustrating misconception of what doing science is like. All that's needed to break through is someone else to tell you to just "run THIS experiment". Oh that's so easy, thanks, why didn't I think of that?
November 19, 2025 at 12:42 PM
This is a frustrating misconception of what doing science is like. All that's needed to break through is someone else to tell you to just "run THIS experiment". Oh that's so easy, thanks, why didn't I think of that?
Oh I’m very interested in joining. Thanks for sharing! I’ve requested to join the google group.
November 11, 2025 at 4:09 PM
Oh I’m very interested in joining. Thanks for sharing! I’ve requested to join the google group.
Reposted by Morgan Thompson
When you are using the "AI" framing, does the way you talk about "AI" carry water for the Sam Altmans of the world? That is, are you helping to paint a picture of their tech as inevitable, all powerful, and/or anything other than commercial products?
>>
>>
November 10, 2025 at 8:35 PM
When you are using the "AI" framing, does the way you talk about "AI" carry water for the Sam Altmans of the world? That is, are you helping to paint a picture of their tech as inevitable, all powerful, and/or anything other than commercial products?
>>
>>
What I find interesting is the comparison of medication to address women’s pain. In France, very low quality evidence of efficacy is permitted, if it is safe. In the US, the evidence needed for efficacy is extremely high, which means many patients remain in pain (incl those in RCT control cond).
October 30, 2025 at 12:16 PM
What I find interesting is the comparison of medication to address women’s pain. In France, very low quality evidence of efficacy is permitted, if it is safe. In the US, the evidence needed for efficacy is extremely high, which means many patients remain in pain (incl those in RCT control cond).